MedImmune, Inc.
Officials at MedImmune, Inc., announce latest news and research developments
Published in Medicine and Law Weekly, September 28th, 2007
This trend article is an immediate alert from NewsRx to identify the most recent news developments at MedImmune, Inc.
Report 1: MedImmune, Inc. announced that it has begun dosing at-risk children six months to 24 months of age in a Phase 1 trial of a vaccine designed to help prevent respiratory syncytial virus (RSV) and parainfluenza virus type 3 (PIV-3) infections, two of the most important causes of lower respiratory tract illness and hospitalization in infants and young children. A previously completed study in healthy adults and non-susceptible older children...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medicine and Law Weekly
More Articles from Medicine and Law Weekly
- Addiction Medicine
Findings from University of Connecticut, Health Center broaden understanding of addiction medicine - Bioengineering
Research reports on bioengineering from University of Aveiro provide new insights - Bioethics
Researchers' work from National Tokyo Medical Center, Division of Clinical Epidemiology focuses on bioethics - Biomedicine
Scientists at University of Illinois report research in biomedicine - Biomedicine
Scientists at University of Sydney discuss research in biomedicine - Cardiology
Findings from University of Michigan, Department of Internal Medicine in cardiology reported - More from this issue of Medicine and Law Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
